CONGRESS #EHA2022 | Michael Dickinson presents the latest data of glofitamab, CD20xCD3 bispecific, in patients with r/r DLBCL and a median of 3 PL, including #CARTcell. The primary endpoint was met: fixed-duration treatment led to a 39.4% CR rate #lymphoma #lymsm

Congrats to Prof Sant-Rayn Pasricha on the Australian Academy of Health and Medical Sciences Jian Zhou Medal - Santa is a true guru of iron and does awesome research in iron, anaemia, and global health. Very well-deserved! Haematology Peter MacCallum CC & Royal Melbourne Jeff Szer Thomas Eliot Lew

Delighted that #glofitamab pivotal data for DLBCL is now online NEJM. 39.4% CR in patients with the most common aggressive #lymphoma, Fixed course, durable remissions, good safety profile, I hope this data changes practice for patients with R/R #DLBCL #ASH22 #lymsm Martin Hutchings

We had a lovely interview here at #ASH22 with Adrian Minson of Haematology Peter MacCallum CC & Royal Melbourne on the Tarmac study, novel combinations in NHL, PET-adapted therapy in DLBCL & more! ASH #LymSM #ImmunoOnc #CARTcell #HemOnc #DLBCL

Haematology Peter MacCallum CC & Royal Melbourne

Results of a multi-centre Peter Mac Cancer Centre trial of #CART + #ibrutinib in #mantle cell #lymphoma were presented at #ASH22 by Adrian Minson Durable responses even in high-risk subtypes. Thx to Chan Cheah A/Prof Nada Hamad for contributing #lymsm bit.ly/3jxXLGF

We are looking for a clinical data manager to join our team and contribute to research and quality projects in haematology. bit.ly/3vYjP0h

Well deserved kudos for our colleague who is not only productive researcher and clinician, but also a great mentor to others.

This is everything. monica slavin Adelaide Oval #asid23

Faster stronger fitter! #Rapcabtagene autoleucel #YTB323 RAPID autologous #CART for #DLBCL #lymphoma: The preclinical and early clinical paper now Cancer Discovery online bit.ly/3qnaf7h So proud of this -and thanks to Peter Mac Cancer Centre Haematology Peter MacCallum CC & Royal Melbourne #lymsm

#pembrolizumab is deliverable and effective as a monotherapy first treatment of #hodgkin #lymphoma in very frail patients. Pleased to present #EHA2023 European Hematology Association and more detail to follow International Conference on Malignant Lymphoma Thanks to sites for years of effort! Judith Trotman #lymsm Peter Mac Cancer Centre

Adrian Minson presented the preliminary results from our Aussie IIT of #glofitamab in combination with RCHP-Pola or RCHOP as first treatment in high risk younger patients with #DLBCL European Hematology Association #EHA2023 #lymsm Thanks to our sites and Peter Mac Cancer Centre Haematology Peter MacCallum CC & Royal Melbourne Peter Mac Research

Venetoclax: a fantastic WEHI (Walter and Eliza Hall Institute) The Royal Melbourne Hospital Haematology Peter MacCallum CC & Royal Melbourne Melbourne success story (with collab Dana-Farber) - great to see the fab Mary Ann presenting it #EHA2023 #VitaminV Thomas Eliot Lew Dr Victor Lin Matthew Davids, MD, MMSc Mark Dawson Michael Dickinson

#CART and fixed #ibrutinib for #Mantle cell #lymphoma in @bloodjournal. More evidence that immunotherapy may help with high-risk molecular subtypes. Congrats to @adrianminson for driving this lightning-fast @petermacres IIT as part of his PHD! #lymsm bit.ly/3Q73904

Amazing science and clinical advances from the #blood2023 Presidential Symposium - an honour to co-chair this session HSANZ THANZ

CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study ashpublications.org/blood/article-… 👉A really smart study w/ time-limit BTK in a difficult to treat #lymphoma, esp p53 mutated. @BloodJournal | ASH @michaeldi

👇🏾This guy is a superstar 🤩

So pleased to work with Jennifer Crombie, MD @falchi_Lorenzo and a great team of authors from around the world and from a variety of treatment settings on these recommendations for #bispecifics. Now available @bloodjournal #lymsm Lymphoma Research Foundation @lymphomaoz bit.ly/3SvFfhl

Congratulations to the big team that made this IIT happen!

#Glofitamab is very active in #mantle cell #lymphoma: Very pleased to show it in this data now available Journal of Clinical Oncology bit.ly/4exf9Tq big thanks to co-investigators @lymphclinician et al, and to my team @haem_pmcc_rmh #lymsm Peter Mac Cancer Centre